Холандија - Холандски - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

baxter b.v. kobaltweg 49 3542 ce utrecht - alanine, l- 4,66 g/l ; arginine, (l-) 4,89 g/l ; asparaginezuur, l 3,5 g/l ; calcium (ca2+) 6,2 mmol/l ; calciumchloride 2-water (e 509) 2,06 g/l samenstelling overeenkomend met ; calciumchloride 0-water (e 509) 1,56 ; cysteÏne (l-) 1,1 g/l ; fenylalanine, (l-) 2,45 g/l ; fosfaat (3-) 8,7 mmol/l ; glucose 1-water 550 g/l samenstelling overeenkomend met ; glucose 0-water 500 g/l ; glutaminezuur (l-) (+) (e 620) 5,83 g/l ; glycero-1(2)dinatriumfostfaat (4-6)-water 4,43 g/l ; glycine (e 640) 2,33 g/l ; histidine, (l-) 2,21 g/l ; isoleucine, (l-) 3,9 g/l ; kaliumacetaat (e 261) 5,05 g/l ; leucine, (l-) 5,83 g/l ; lysine (l-) 1-water 7,2 g/l samenstelling overeenkomend met ; lysine, (l-) 6,41 g/l ; magnesiumacetaat 4-water 1,51 g/l samenstelling overeenkomend met ; magnesiumacetaat 0-water 1,02 g/l ; methionine, (l-) 1,4 g/l ; natriumchloride 1,37 g/l ; olijfolie, gezuiverd 100 g/l ; ornithinehydrochloride (l-) 1,85 g/l samenstelling overeenkomend met ; ornithine (l-) 1,45 g/l ; proline, (l-) 1,75 g/l ; serine, (l-) 2,33 g/l ; sojaolie, gezuiverd 25 g/l ; taurine 0,35 g/l ; threonine, (l-) 2,16 g/l ; tryptofaan, (l-) 1,17 g/l ; tyrosine, (l-) 0,45 g/l ; valine, (l-) 4,43 g/l ; samenstelling overeenkomend met acetaat (c2h3o2)- 29 mmol/l ; chloride (cl-) 28 mmol/l ; kalium (k+) 23 mmol/l ; magnesium (mg2+) 3,1 mmol/l ; malaat (d,l)(2-) 9 mmol/l ; natrium (na+) 24 mmol/l - emulsie voor infusie - appelzuur, (l-)(-)(e 296) ; ei fosfatiden, gezuiverd ; glycerol (e 422) ; natriumhydroxide (e 524) ; natriumoleaat (e 470a) ; water voor injectie ; zoutzuur (e 507), - combinations

Холандија - Холандски - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

baxter b.v. kobaltweg 49 3542 ce utrecht - alanine, l- 4,66 g/l ; arginine, (l-) 4,89 g/l ; asparaginezuur, l 3,5 g/l ; calciumchloride 2-water (e 509) 1,44 g/l samenstelling overeenkomend met ; calciumchloride 0-water (e 509) 1,09 g/l ; cysteÏne (l-) 1,1 g/l ; fenylalanine, (l-) 2,45 g/l ; glucose 1-water 550 g/l samenstelling overeenkomend met ; glucose 0-water 500 g/l ; glutaminezuur (l-) (+) (e 620) 5,83 g/l ; glycero-1(2)dinatriumfostfaat (4-6)-water 5,65 g/l ; glycine (e 640) 2,33 g/l ; histidine, (l-) 2,21 g/l ; isoleucine, (l-) 3,9 g/l ; kaliumacetaat (e 261) 8 g/l ; leucine, (l-) 5,83 g/l ; lysine (l-) 1-water 7,2 g/l samenstelling overeenkomend met ; lysine, (l-) 6,41 g/l ; magnesiumacetaat 4-water 1,4 g/l samenstelling overeenkomend met ; magnesiumacetaat 0-water 0,94 g/l ; methionine, (l-) 1,4 g/l ; natriumchloride 4,57 g/l ; olijfolie, gezuiverd 100 g/l ; ornithinehydrochloride (l-) 1,85 g/l samenstelling overeenkomend met ; ornithine (l-) 1,45 g/l ; proline, (l-) 1,75 g/l ; serine, (l-) 2,33 g/l ; sojaolie, gezuiverd 25 g/l ; taurine 0,35 g/l ; threonine, (l-) 2,16 g/l ; tryptofaan, (l-) 1,17 g/l ; tyrosine, (l-) 0,45 g/l ; valine, (l-) 4,43 g/l ; samenstelling overeenkomend met acetaat (c2h3o2)- 37 mmol/l ; calcium (ca2+) 3,8 mmol/l ; chloride (cl-) 43 mmol/l ; fosfaat (3-) 9,4 mmol/l ; kalium (k+) 32 mmol/l ; magnesium (mg2+) 2,6 mmol/l ; malaat (l-)( 2-) 9 mmol/l ; natrium (na+) 46 mmol/l - emulsie voor infusie - appelzuur, (l-)(-)(e 296) ; ei fosfatiden, gezuiverd ; glycerol (e 422) ; natriumhydroxide (e 524) ; natriumoleaat (e 470a) ; water voor injectie ; zoutzuur (e 507), - combinations

Белгија - Холандски - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

baxter - alanine; arginine; asparaginezuur; cysteïne; glutaminezuur; glycine; isoleucine; histidine; leucine; lysinemonohydraat; methionine; ornithinehydrochloride; fenylalanine; proline; serine; taurine; threonine; tryptofaan; tyrosine; valine; kaliumacetaat; calciumchloridedihydraat; magnesiumacetaattetrahydraat; natriumglycerofosfaathydraat; glucosemonohydraat; sojabeenolie + olijfolie - emulsie voor infusie - alanine 2.5 mg/ml; arginine 2.6 mg/ml; asparaginezuur 1.867 mg/ml; cysteïne 0.6 mg/ml; glutaminezuur 3.1 mg/ml; glycine 1.233 mg/ml; isoleucine 2.067 mg/ml; histidine 1.167 mg/ml; leucine 3.1 mg/ml; lysinemonohydraat 3.833 mg/ml; methionine 0.733 mg/ml; ornithinehydrochloride 1 mg/ml; fenylalanine 1.3 mg/ml; proline 0.933 mg/ml; serine 1.233 mg/ml; taurine 0.2 mg/ml; threonine 1.167 mg/ml; tryptofaan 0.633 mg/ml; tyrosine 0.233 mg/ml; valine 2.367 mg/ml; kaliumacetaat 2.033 mg/ml; calciumchloridedihydraat 1.833 mg/ml; magnesiumacetaattetrahydraat 0.333 mg/ml; natriumglycerofosfaathydraat 3.267 mg/ml; glucosemonohydraat 146.667 mg/ml; sojabeenolie + olijfolie 25 mg/ml - combinations

Белгија - Холандски - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

baxter sa-nv - natriumglycerofosfaathydraat - eq. natriumglycerofosfaat 2210 mg; glycine 910 mg; glutaminezuur 2290 mg; valine 1740 mg; arginine 1920 mg; leucine 2290 mg; serine 910 mg; proline 690 mg; alanine 1830 mg; histidine 870 mg; threonine 850 mg; tryptofaan 460 mg; magnesiumacetaat 0,55 mg/ml; natriumchloride 1790 mg; dl-asparaginezuur 1370 mg; ornithine hydrochloride 730 mg - eq. ornithine 570 mg; kaliumacetaat 3140 mg/ml; taurine 140 mg; cysteïne 430 mg; sojaolie + olijfolie 28,1 g; lysinemonohydraat 2,82 mg/ml - eq. lysine 2,51 mg/ml; glucosemonohydraat 210,65 g/l - eq. glucose 191,5 g/l; calciumchloridedihydraat 0,56 g/l; tyrosine 180 mg; isoleucine 1530 mg; methionine 550 mg; fenylalanine 960 mg - emulsie voor infusie - proline 690 mg; dl-asparaginezuur 1370 mg; sojabeenolie + olijfolie 28.1 g; kaliumacetaat 3140 mg/ml; ornithinehydrochloride 730 mg; glutaminezuur 2290 mg; glucosemonohydraat; histidine 870 mg; arginine 1920 mg; valine 1740 mg; taurine 140 mg; glycine 910 mg; threonine 850 mg; alanine 1830 mg; cysteïne 430 mg; isoleucine 1530 mg; calciumchloridedihydraat; natriumglycerofosfaathydraat; tyrosine 180 mg; natriumchloride 1790 mg; lysinemonohydraat 2.82 mg/ml; serine 910 mg; fenylalanine 960 mg; tryptofaan 460 mg; methionine 550 mg; leucine 2290 mg; magnesiumacetaat 0.55 mg/ml - combinations

Белгија - Холандски - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

baxter sa-nv - natriumglycerofosfaathydraat 3,267 mg/ml; magnesiumacetaattetrahydraat 0,333 mg/ml; glycine 1,233 mg/ml; glutaminezuur 3,1 mg/ml; valine 2,367 mg/ml; arginine 2,6 mg/ml; leucine 3,1 mg/ml; serine 1,233 mg/ml; proline 0,933 mg/ml; alanine 2,5 mg/ml; histidine 1,167 mg/ml; threonine 1,167 mg/ml; tryptofaan 0,633 mg/ml; ornithine hydrochloride 1 mg/ml - eq. ornithine 230 mg; kaliumacetaat 2,033 mg/ml; taurine 0,2 mg/ml; cysteïne 0,6 mg/ml; sojaolie + olijfolie 25 mg/ml; lysinemonohydraat 3,833 mg/ml - eq. lysine 3,433 mg/ml; asparaginezuur 1,867 mg/ml; glucosemonohydraat 146,667 mg/ml - eq. watervrij glucose 133,333 mg/ml; calciumchloridedihydraat 1,833 mg/ml; tyrosine 0,233 mg/ml; isoleucine 2,067 mg/ml; methionine 0,733 mg/ml; fenylalanine 1,3 mg/ml - emulsie voor infusie - combinations

Холандија - Холандски - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

huvepharma nv - florfenicol - granulaat voor gebruik in drinkwater - florfenicol 200 mg/g, - florfenicol - varkens

Европска Унија - Холандски - EMA (European Medicines Agency)

stada arzneimittel ag - adalimumab - arthritis, psoriatic; arthritis, juvenile rheumatoid; arthritis, rheumatoid; colitis, ulcerative; crohn disease; hidradenitis suppurativa; psoriasis; spondylitis, ankylosing; uveitis - immunosuppressiva - rheumatoid arthritishukyndra in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs (dmards) including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. hukyndra can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. adalimumab is aangetoond dat het verminderen van de snelheid van progressie van gewrichtsschade, zoals gemeten door de x-ray en verbetering van fysiek functioneren, indien gegeven in combinatie met methotrexaat. juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritishukyndra in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more dmard. hukyndra can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5. adalimumab is niet onderzocht bij patiënten jonger dan 2 jaar. enthesitis-related arthritishukyndra is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritisankylosing spondylitis (as)hukyndra is indicated for the treatment of adults with severe active as who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of ashukyndra is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (nsaids). psoriatic arthritishukyndra is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous dmard therapy has been inadequate. adalimumab is aangetoond dat het verminderen van de snelheid van progressie van perifere gewrichtsschade, zoals gemeten door de x-ray bij patiënten met polyarticulaire symmetrische subtypen van de ziekte (zie hoofdstuk 5. 1) en aan het verbeteren van de fysieke functie. psoriasishukyndra is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasishukyndra is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)hukyndra is indicated for the treatment of active moderate to severe hs (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 en 5. crohn’s diseasehukyndra is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseasehukyndra is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitishukyndra is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. paediatric ulcerative colitishukyndra is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitishukyndra is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitishukyndra is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Европска Унија - Холандски - EMA (European Medicines Agency)

stada arzneimittel ag - adalimumab - arthritis, rheumatoid; arthritis, juvenile rheumatoid; spondylitis, ankylosing; arthritis, psoriatic; psoriasis; hidradenitis suppurativa; crohn disease; colitis, ulcerative; uveitis - immunosuppressiva - rheumatoid arthritislibmyris in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs (dmards) including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. libmyris can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. adalimumab is aangetoond dat het verminderen van de snelheid van progressie van gewrichtsschade, zoals gemeten door de x-ray en verbetering van fysiek functioneren, indien gegeven in combinatie met methotrexaat. juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritislibmyris in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more dmard. libmyris can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5. adalimumab is niet onderzocht bij patiënten jonger dan 2 jaar. enthesitis-related arthritislibmyris is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. axial spondyloarthritisankylosing spondylitis (as)libmyris is indicated for the treatment of adults with severe active as who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of aslibmyris is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (nsaids). psoriatic arthritislibmyris is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous dmard therapy has been inadequate. adalimumab is aangetoond dat het verminderen van de snelheid van progressie van perifere gewrichtsschade, zoals gemeten door de x-ray bij patiënten met polyarticulaire symmetrische subtypen van de ziekte en het verbeteren van fysieke functie. psoriasislibmyris is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasislibmyris is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)libmyris is indicated for the treatment of active moderate to severe hs (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 en 5. crohn’s diseaselibmyris is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseaselibmyris is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitislibmyris is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. paediatric ulcerative colitislibmyris is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitislibmyris is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitislibmyris is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Холандија - Холандски - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

intervet nederland b.v. - cimetidine - tablet - cimetidine 100 mg/stuk, - cimetidine - honden

Холандија - Холандски - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

intervet nederland b.v. - cimetidine - tablet - cimetidine 200 mg/stuk, - cimetidine - honden